✦Licensed US Providers✦HSA/FSA Eligible✦HIPAA Compliant✦Free Discreet Shipping✦Cancel Anytime
READY
Get Started
STATESABOUT
START FREE CONSULTATION →

No charge until provider approval

GLP-1 Users · Ozempic · Wegovy · Mounjaro · DEEP BREATH™ by READY

Ozempic
changed
your body.

It may have also
changed your desire.

You're not alone. With 40M+ Americans on semaglutide or tirzepatide, reduced libido and emotional disconnection are among the most commonly reported — and least discussed — side effects.

Free consultation · Takes 2 minutes · No charge until approved

DEEP BREATH™ Nasal Spray

40M+

Americans on GLP-1 agonists

IQVIA, 2024

182

Sexual adverse events reported to FDA FAERS (2024–2025)

Statistically significant p<0.0001

0

Clinically significant interactions identified in available literature

Consult your provider

The Science

Why this
happens.

Neurochemical Pathways

GLP-1 agonists work by increasing serotonergic activity at the 5-HT2C receptor. That same mechanism suppresses sexual desire — it's the same pathway as SSRI-induced sexual dysfunction. The effect is real. And it's rarely discussed.

Oxytocin operates on entirely different neurochemical pathways — oxytocinergic and dopaminergic. It doesn't compete with your GLP-1 medication. It complements it.

View the full science →
DEEP BREATH™ Nasal Spray

DEEP BREATH™

Your Plan.

Prescribed alongside your existing GLP-1 therapy. Your provider reviews the full picture.

Quarterly

Best Value

3 bottles · Priority shipping · Save $90

$119/mo

Monthly

1 bottle · Cancel anytime after 2 months

$129/mo

Talk to a Provider

Prescription required. Not FDA-approved. No charge until provider approval.

Common Questions · GLP-1 Users Ask

GLP-1
Users Ask.

Start Consultation

Free · Takes 2 minutes · No charge until approved

Oxytocin operates on oxytocinergic and dopaminergic pathways, entirely separate from GLP-1 receptor mechanisms. Your DEEP BREATH™ provider will review your complete medication list during the consultation and make the final determination.

We recommend informing your prescribing physician. Your DEEP BREATH™ provider will document all current medications in your consultation intake to ensure a complete clinical picture.

In the Muin et al. 2015 clinical trial, participants reported improvements within the first weeks of use. Individual results vary. Your provider will discuss realistic expectations during your consultation.

DEEP BREATH™ is currently available in California, Florida, Texas, New York, Nevada, Colorado, Arizona, Georgia, Illinois, Washington, and Oregon. Join the waitlist if your state is not listed.